Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 1.00 |
| ▸ | ITGAV | P06756 | 20/20 | 1.00 |
| ▸ | ITGB6 | P18564 | 19/20 | 1.00 |
| ▸ | ITGB5 | P18084 | 19/20 | 1.00 |
| ▸ | ITGB8 | P26012 | 18/20 | 1.00 |
| ▸ | ITGB1 | P05556 | 16/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.78 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17629325 | 1.00 | ITGB3 (1.00) | ITGB3ITGAVITGB6ITGB5ITGB8 | |
| SCHEMBL17640916 | 1.00 | ITGB3 (1.00) | ITGB3ITGAVITGB6ITGB5ITGB8 | |
| SCHEMBL17629329 | 1.00 | ITGB3 (1.00) | ITGB3ITGAVITGB6ITGB5ITGB8 | |
| SCHEMBL17640886 | 1.00 | ITGB3 (1.00) | ITGB3ITGAVITGB6ITGB5ITGB8 | |
| SCHEMBL19449035 | 0.94 | ITGB3 (0.88) | ITGB3ITGAVITGB6ITGB5ITGB8 | |
| SCHEMBL19449026 | 0.94 | ITGB3 (0.88) | ITGB3ITGAVITGB6ITGB5ITGB8 | |
| SCHEMBL19449034 | 0.94 | ITGB3 (0.88) | ITGB3ITGAVITGB6ITGB5ITGB8 | |
| Hydrochloric Acid SCHEMBL25379415 | 0.92 | ITGB3 (0.86) | ITGB3ITGAVITGB6ITGB5ITGB8 | |
| Hydrochloric Acid SCHEMBL25379412 | 0.92 | ITGB3 (0.86) | ITGB3ITGAVITGB6ITGB5ITGB8 | |
| SCHEMBL26203566 | 0.92 | ITGB3 (0.86) | ITGB3ITGAVITGB6ITGB5ITGB8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3197895-B1 | NAPHTHYRIDINE DERIVATIVES AS ALPHA V BETA 6 INTEGRIN ANTAGONISTS FOR THE TREATMENT OF FIBROTIC DISEASES | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-03-11 | — | — | EP | claimed |
| US-10004724-B2 | Compounds alpha v beta 6 integrin antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-26 | — | — | US | claimed |
| US-20170290818-A1 | NOVEL COMPOUNDS ALPHA v BETA 6 INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-12 | — | — | US | claimed |
| EP-3197895-A1 | NOVEL COMPOUNDS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2017-08-02 | — | — | EP | claimed |
| WO-2016046241-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-03-31 | — | — | WO | claimed |
| EP-3197895-B1 | NAPHTHYRIDINE DERIVATIVES AS ALPHA V BETA 6 INTEGRIN ANTAGONISTS FOR THE TREATMENT OF FIBROTIC DISEASES | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-03-11 | — | — | EP | disclosed |
| US-10004724-B2 | Compounds alpha v beta 6 integrin antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-06-26 | — | — | US | disclosed |
| US-20170290818-A1 | NOVEL COMPOUNDS ALPHA v BETA 6 INTEGRIN ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-12 | — | — | US | disclosed |
| EP-3197895-A1 | NOVEL COMPOUNDS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2017-08-02 | — | — | EP | disclosed |
| WO-2016046241-A1 | NOVEL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10004724-B2 | Compounds alpha v beta 6 integrin antagonists | ITGAV, ITGB6, ITGB1 | ITGB3 7/4885ITGAV 1/4885ITGB6 2/4885 |
| US-20170290818-A1 | NOVEL COMPOUNDS ALPHA v BETA 6 INTEGRIN ANTAGONISTS | ITGAV, ITGB6, ITGB1 | ITGB3 7/4885ITGAV 1/4885ITGB6 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.